Collegium Pharmaceutical Inc (COLL) Stock: What Does the Chart Say Tuesday?

The market has been high on Collegium Pharmaceutical Inc (COLL) stock recently. COLL gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Collegium Pharmaceutical Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on COLL!

See Full COLL Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With COLL Stock Today?

Collegium Pharmaceutical Inc (COLL) stock has risen 1.68% while the S&P 500 has fallen -0.35% as of 11:16 AM on Tuesday, Nov 21. COLL has risen $0.43 from the previous closing price of $25.59 on volume of 41,187 shares. Over the past year the S&P 500 is up 14.72% while COLL has risen 20.74%. COLL earned $0.07 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 360.69. To see InvestorsObserver's Sentiment Score for Collegium Pharmaceutical Inc click here.

More About Collegium Pharmaceutical Inc

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. It is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release & immediate-release formulations of tapentadol. Click Here to get the full Stock Report for Collegium Pharmaceutical Inc stock.